Detalhe da pesquisa
1.
A global core outcome measurement set for snakebite clinical trials.
Lancet Glob Health
; 11(2): e296-e300, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36669810
2.
[A global core outcome measurement set for snakebite clinical trials]. / Définition d'un jeu universel de critères de décision de base pour les essais cliniques sur les morsures de serpent.
Med Trop Sante Int
; 3(3)2023 09 30.
Artigo
em Francês
| MEDLINE | ID: mdl-38094484
3.
Development of tetravalent, bispecific CCR5 antibodies with antiviral activity against CCR5 monoclonal antibody-resistant HIV-1 strains.
Antimicrob Agents Chemother
; 55(5): 2369-78, 2011 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21300827
4.
RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients.
J Infect Dis
; 202(10): 1510-9, 2010 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20942646
5.
Epitope switching as a novel escape mechanism of HIV to CCR5 monoclonal antibodies.
Antimicrob Agents Chemother
; 54(2): 734-41, 2010 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19995923
6.
Clinical trials in the pandemic age: What is fit for purpose?
Gates Open Res
; 4: 58, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32656501
7.
GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796.
Antimicrob Agents Chemother
; 53(5): 2129-32, 2009 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-19273674
8.
Modulation of alpha interferon anti-hepatitis C virus activity by ISG15.
J Gen Virol
; 90(Pt 12): 2929-2939, 2009 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-19656964
9.
Impact of the enfuvirtide resistance mutation N43D and the associated baseline polymorphism E137K on peptide sensitivity and six-helix bundle structure.
Biochemistry
; 47(25): 6662-70, 2008 Jun 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-18507398
10.
The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors.
Antimicrob Agents Chemother
; 52(5): 1604-12, 2008 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-18285474
11.
Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479.
Antimicrob Agents Chemother
; 52(12): 4356-69, 2008 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-18838588
12.
Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients.
J Antimicrob Chemother
; 61(6): 1205-16, 2008 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-18343801
13.
Closing two doors of viral entry: intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1.
Virol J
; 5: 56, 2008 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18452606
14.
A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.
PLoS Med
; 4(1): e36, 2007 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-17227139
15.
Novel CCR5 monoclonal antibodies with potent and broad-spectrum anti-HIV activities.
Antiviral Res
; 74(2): 125-37, 2007 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-17166600
16.
Development of a novel dual CCR5-dependent and CXCR4-dependent cell-cell fusion assay system with inducible gp160 expression.
J Biomol Screen
; 11(1): 65-74, 2006 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-16314403
17.
Development of a Moloney murine leukemia virus-based pseudotype anti-HIV assay suitable for accurate and rapid evaluation of HIV entry inhibitors.
J Biomol Screen
; 11(6): 652-63, 2006 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-16844967
18.
Two-metal ion mechanism of RNA cleavage by HIV RNase H and mechanism-based design of selective HIV RNase H inhibitors.
Nucleic Acids Res
; 31(23): 6852-9, 2003 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-14627818
19.
Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates.
AIDS
; 18(13): 1787-94, 2004 Sep 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-15316339
20.
Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial).
AIDS
; 16(11): 1479-87, 2002 Jul 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-12131185